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Metastatic brain tumors are the most common intra-
cranial neoplasm in adults with approximately 40–50%
of cases secondary to lung cancer [1]. Many treatment
modalities including surgery, whole brain radiother-
apy (WBRT) and chemotherapy have been used to
maximize survival time, provide local control, and
improve neurological function [2]. However, the man-
agement of patients with recurrent metastatic brain
tumors treated by prior surgery and WBRT remains 
a challenge for clinical physicians. Surgical interven-
tion has been the primary treatment opinion for this
condition before the development of stereotactic radio-
surgery (SRS). SRS has been proven efficacious in the
management of metastatic brain tumor, especially
when the tumor has recurred after previous WBRT.
SRS combines the principles of stereotactic local-
ization, with multiple radiation beam trajectories, to
deliver a high dose of radiation to the treatment site and
minimize exposure to normal tissue [3]. The method
was first developed in 1951 by Leksell [3], who used
a stereotactic frame to focus radiation from a cobalt
source through a series of collimators on a brain lesion.
During the past several decades, this noninvasive tech-
nique, combined with new advances in radiosurgery,
has proven to be effective in the ablation of intracranial
lesions.
The CyberKnife is a new image-guided frameless
and real-time robotic SRS system that is capable of
delivering a highly precise radiation beam using to-
mography [4]. The greater tumor control rate in smaller
metastatic brain tumors measuring less than 1 cm3 has
already been demonstrated using this technique [5–7].
However, the complete response of larger metastatic
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Stereotactic radiosurgery plays an important role in management of metastatic brain tumors,
especially when the tumor has recurred after treatment with previous whole brain radiotherapy.
Most metastatic brain tumors less than 1 cm3 show a complete response after stereotactic radio-
surgery. However, there are few reports of a dramatic change in the complete response of large
metastatic brain tumors. Here, we report a case of adenocarcinoma of lung that had metastasized
to the brain. Because the recurrence of the metastatic brain tumor measured approximately 3 cm
in diameter, the tumor was previously treated with two prior craniotomies followed by whole
brain radiation to the resection cavity. The tumor subsequently recurred and was treated with
stereotactic radiosurgery (CyberKnife). A dramatic response was noted 3 months after radiosurgery
with complete disappearance of the recurrent tumor.
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brain tumors after CyberKnife therapy has been rarely
discussed [6]. We report a case of a 3 cm (in diameter)
metastatic brain tumor that was initially treated by
surgical intervention and WBRT. The tumor subse-
quently recurred and was treated with CyberKnife
SRS with a dramatic response to the new therapy.
CASE PRESENTATION
A 56-year-old man presented with blurred vision, head-
ache, and weakness in the left lower leg for 1 month
prior to his hospital admission on June 6, 2005. On
admission, a neurological examination revealed left
hemianopsia and grade 4/5 decreased muscle strength
in the left lower leg. Magnetic resonance imaging (MRI)
demonstrated a 5.7 cm rim-enhancing lesion in the
right parieto-occipital lobe and a 1.9 cm rim-enhancing
lesion in the left temporal lobe, which were both highly
suspicious for brain metastases. Because of the patient’s
progressive symptoms, he underwent craniotomy to
remove the tumor in the parieto-occipital lobe on June
20, and a repeat craniotomy on July 4 was performed
to remove the tumor in the left temporal lobe. The
pathology reports confirmed the diagnosis of metasta-
tic adenocarcinoma of the lung. WBRT (3,000 cGy/15
fractions) was administered from November 3 to
November 23.
A follow-up brain MRI scan on November 14 re-
vealed a rim-enhancing cystic lesion measuring 4.6 cm
in maximal diameter in the right parieto-occipital region
compatible with recurrence and the patient under-
went another craniotomy on November 28. However,
on February 14, 2007, additional computed tomogra-
phy and MRI showed a 3 cm (in diameter) recurrent
tumor in the right occipital region (Figures 1A and 1B).
Because the size of the tumor was so large and no
obvious neurological deficits were present, SRS with
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Figure 1. (A) Pre-stereotactic radiosurgery (SRS) computed tomography of the brain shows a heterogeneously contrast-enhanced
tumor mass approximately 3 cm in diameter, located in the right parieto-occipital lobe. (B) Pre-SRS T1-weighted axial images of magnetic
resonance imaging show a contrast-enhanced tumor mass in the right parieto-occipital lobe. (C) Two months after CyberKnife SRS,
computed tomography of the brain revealed a reduced tumor mass without obvious peritumoral edema. (D) Three months after CyberKnife
SRS, T1-weighted axial images of magnetic resonance imaging revealed the disappearance of the tumor mass with complete response.
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CyberKnife was indicated. On October 12, 2007 our
patient received CyberKnife SRS with a marginal
dose of 1,500 cGy delivered to the 80% isodose line.
The treated tumor volume was 23,771 mm3 with
98.1% tumor coverage. The conformity index was 1.43
and the modified conformity index was 1.46 (Figure 2).
During regular follow-up, there were no side effects
due to the radiation and the tumor shrunk within 2
months (Figure 1C) and had completely disappeared
within 3 months (Figure 1D).
DISCUSSION
The exact incidence of metastatic brain tumors remains
unknown but has been estimated at approximately
200,000 cases per year [2]. If left untreated, the median
survival time is approximately 1–2 months [6]. Various
treatments, including surgery, chemotherapy, WBRT
or combined modalities, have been shown to prolong
survival time and improve neurological outcome [2].
Factors such as the age, clinical performance status
(Karnofsky score), systematic disease and the number,
size, volume, and location of the tumor can predict
the outcome after these therapies [8,9].
Although glucocorticoids and WBRT have been
the mainstay of treatment for metastatic brain tumors,
craniotomy for tumor resection has been the stan-
dard therapy for local control [10]. The median sur-
vival time in patients with metastatic brain tumors
treated with additional WBRT remains limited to 3–6
months [11]. However, if the metastatic brain tumor
Figure 2. Planning of CyberKnife stereotactic radiosurgery.
recurs after WBRT, the next-step in management of
these tumors remains a challenge for neurosurgeons
because surgical intervention may be the only option.
SRS uses multiple convergent beams to deliver 
a single large dose of radiation to a discrete target
volume and is an alternative treatment for patients
with metastatic brain tumors that are surgically unre-
sectable or located in the eloquent brain areas [2,12].
Numerous studies have reported the effects of cran-
iotomy alone compared with WBRT alone, SRS alone,
and combined modalities for the management of meta-
static brain tumors [2,10–13]. SRS has been proven an
effective alternative and noninvasive treatment for
metastatic brain tumors. In two series of non-small
cell lung cancer with brain metastasis, SRS afforded
effective local tumor control in approximately 84–94%
of patients with a prolonged median survival time of
approximately 15 months [12,14,15].
The CyberKnife is an image-guided frameless, real-
time robotic radiosurgery system [4]. The benefits 
of the CyberKnife include more accurate target local-
ization and better dose delivery for management of
metastatic brain tumors [4–7]. To date, the local tumor
control rate has been approximately 83%, which is com-
parable to other radiosurgery systems [16]. Shimamoto
et al recently studied 48 patients with metastatic
brain tumors, with the majority from lung primaries,
treated with CyberKnife stereotactic irradiation. They
demonstrated complete response to the CyberKnife
with non-visualization of the previously enhancing
lesions on subsequent imaging when the clinical tar-
get volume was less than 1 cm3 [6]. This result sug-
gests that smaller tumors have fewer propensities for
progression and a lesser dose tolerance. Fractionated
modality has been considered for the control of larger
tumors. However, the complete response of larger
metastatic brain tumors (≥1 cm3) has not yet been
demonstrated.
In our case, the recurrence of metastatic brain tumor
following craniotomy with removal of the tumor and
WBRT was observed during the follow-up neuro-
imaging studies. After CyberKnife radiosurgery with
1,500 cGy, the tumor, which initially measured 3 cm
in diameter, completely resolved within 3 months.
In conclusion, the image-guided SRS is especially
useful for lesions that cannot be treated convention-
ally, such as lesions that have received the maximal
radiation dose using conventional WBRT, or post-
operative residual lesions. The complete response 
of metastatic tumors larger than 1 cm3 can also be
achieved within a few months after CyberKnife radio-
surgery, as shown by our case study.
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成功經電腦刀治療轉移性腦瘤：個案報告
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立體放射線手術在治療轉移性腦瘤己扮演重要的角色，尤其針對病灶已接受過全腦放
射線治療仍復發的個案，更顯出其特別的效果。一般大部份小於 1 cm
3
轉移性的腦
瘤，經立體放射線手術治療後，可以完全消失。然而，比較大的轉移性腫瘤卻很少被
報導經治療後，可以完全消失。所以，我們報導一個肺腺瘤轉移至腦部的個案，經過
二次開顱手術及全腦放射線治療後，仍發現有復發，直徑大小約 3 cm。經過電腦刀
治療後，此病灶在三個月後完全消失。
關鍵詞：腦轉移、電腦刀、立體放射線手術
（高雄醫誌 2010;26:144–9）
